Axel Bolte

Axel Bolte was the founder of Inozyme Pharma, Inc. since 2015, holding the title of Director from 2023 to 2025.
Current jobs include Deputy Chairman-Supervisory Board at Nabriva Therapeutics GmbH since 2015 and Director at Tripex Pharmaceuticals LLC.
Former jobs include Vice Chairman at Kolltan Pharmaceuticals, Inc., Independent Director at PTC Therapeutics, Inc. from 2013 to 2014, Director at Lux Biosciences, Inc., Director at ZP Opco, Inc., Director at Adnexus, Director at Newron Pharmaceuticals SpA from 2005 to 2008, Director at Enanta Pharmaceuticals, Inc. from 2005 to 2013, Director at Affinium Pharmaceuticals Ltd., Director at MPEX Pharmaceuticals, Inc. from 2006 to 2011, Independent Director at IVERIC bio, Inc. from 2007 to 2023, Independent Director at Allena Pharmaceuticals, Inc. from 2014 to 2019, Independent Director at Nabriva Therapeutics Plc from 2017 to 2018, Investment Advisor at HBM Partners AG from 2013 to 2017, Principal at Serono SA, Investment Manager at New Medical Technologies AG from 2001 to 2003, and Managing Member at Healthcare Advisors GmbH from 2017 to 2019.
Education includes an undergraduate degree from the University of Cambridge, an MBA from the University of St. Gallen, and a graduate degree from the Swiss Federal Institute of Technology.